Asterand Signs Agreement with Eisai Co.
News May 07, 2010
Asterand plc announces that its subsidiary BioSeek, LLC has signed a two-year collaboration agreement with Eisai Co., Ltd., a research-based human health care company headquartered in Japan.
Under the agreement, BioSeek will apply its proprietary BioMAP® platform to advance Eisai’s multiple discovery projects in the oncology and inflammation areas. The agreement encompasses scientific projects at Eisai sites in the U.S. and Japan. The financial terms include research funding, success milestones payments and license fees: specific terms were not disclosed.
Asterand CEO, Martyn Coombs commented: “We are honoured that Eisai has chosen to incorporate BioSeek’s unique BioMAP® technology platform into its drug discovery process. This master agreement is yet another strong endorsement of our BioMAP® human-based disease model. We look forward to assisting Eisai in its quest to develop new therapies for cancer and inflammatory conditions.”
BioMAP® Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology. Depending on their mechanism of action, drug compounds induce specific patterns of changes in these systems (BioMAP® profiles) that can be compared to a large number of reference profiles in the BioMAP® Database.
BioMAP® provides early insight into human pharmacological and toxicological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds.